Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
56.25
+2.51 (4.67%)
At close: Sep 26, 2025, 4:00 PM EDT
57.00
+0.75 (1.33%)
After-hours: Sep 26, 2025, 6:22 PM EDT
Kymera Therapeutics Stock Forecast
Stock Price Forecast
According to 17 professional analysts, the 12-month price target for Kymera Therapeutics stock ranges from a low of $44 to a high of $79. The average analyst price target of $60.18 forecasts a 6.99% increase in the stock price over the next year.
Price Target: $60.18 (+6.99%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Kymera Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 7 | 7 | 7 | 8 |
| Buy | 5 | 6 | 7 | 7 | 7 | 8 |
| Hold | 3 | 4 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 16 | 16 | 16 | 16 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $60 → $70 | Strong Buy | Maintains | $60 → $70 | +24.44% | Sep 18, 2025 |
| Barclays | Barclays | Buy Initiates $60 | Buy | Initiates | $60 | +6.67% | Sep 17, 2025 |
| RBC Capital | RBC Capital | Buy Initiates $70 | Buy | Initiates | $70 | +24.44% | Sep 16, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $56 → $53 | Buy | Maintains | $56 → $53 | -5.78% | Jun 27, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $57 → $53 | Buy | Maintains | $57 → $53 | -5.78% | Jun 26, 2025 |
Financial Forecast
Revenue This Year
77.08M
from 47.07M
Increased by 63.75%
Revenue Next Year
57.41M
from 77.08M
Decreased by -25.53%
EPS This Year
-3.49
from -2.98
EPS Next Year
-4.17
from -3.49
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 154.3M | 113.7M | |||
| Avg | 77.1M | 57.4M | |||
| Low | 42.7M | 13.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 227.9% | 47.5% | |||
| Avg | 63.8% | -25.5% | |||
| Low | -9.3% | -82.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.60 | -3.29 | |||
| Avg | -3.49 | -4.17 | |||
| Low | -3.84 | -6.20 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.